305 related articles for article (PubMed ID: 22318143)
1. The histone deacetylase inhibitor valproic acid lessens NK cell action against oncolytic virus-infected glioblastoma cells by inhibition of STAT5/T-BET signaling and generation of gamma interferon.
Alvarez-Breckenridge CA; Yu J; Price R; Wei M; Wang Y; Nowicki MO; Ha YP; Bergin S; Hwang C; Fernandez SA; Kaur B; Caligiuri MA; Chiocca EA
J Virol; 2012 Apr; 86(8):4566-77. PubMed ID: 22318143
[TBL] [Abstract][Full Text] [Related]
2. Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase Inhibition.
Jennings VA; Scott GB; Rose AMS; Scott KJ; Migneco G; Keller B; Reilly K; Donnelly O; Peach H; Dewar D; Harrington KJ; Pandha H; Samson A; Vile RG; Melcher AA; Errington-Mais F
Mol Ther; 2019 Jun; 27(6):1139-1152. PubMed ID: 31053413
[TBL] [Abstract][Full Text] [Related]
3. A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases.
Chen X; Han J; Chu J; Zhang L; Zhang J; Chen C; Chen L; Wang Y; Wang H; Yi L; Elder JB; Wang QE; He X; Kaur B; Chiocca EA; Yu J
Oncotarget; 2016 May; 7(19):27764-77. PubMed ID: 27050072
[TBL] [Abstract][Full Text] [Related]
4. TGFβ Treatment Enhances Glioblastoma Virotherapy by Inhibiting the Innate Immune Response.
Han J; Chen X; Chu J; Xu B; Meisen WH; Chen L; Zhang L; Zhang J; He X; Wang QE; Chiocca EA; Kaur B; Caligiuri MA; Yu J
Cancer Res; 2015 Dec; 75(24):5273-82. PubMed ID: 26631269
[TBL] [Abstract][Full Text] [Related]
5. Glioblastoma infiltration of both tumor- and virus-antigen specific cytotoxic T cells correlates with experimental virotherapy responses.
Alayo QA; Ito H; Passaro C; Zdioruk M; Mahmoud AB; Grauwet K; Zhang X; Lawler SE; Reardon DA; Goins WF; Fernandez S; Chiocca EA; Nakashima H
Sci Rep; 2020 Mar; 10(1):5095. PubMed ID: 32198420
[TBL] [Abstract][Full Text] [Related]
6. NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors.
Alvarez-Breckenridge CA; Yu J; Price R; Wojton J; Pradarelli J; Mao H; Wei M; Wang Y; He S; Hardcastle J; Fernandez SA; Kaur B; Lawler SE; Vivier E; Mandelboim O; Moretta A; Caligiuri MA; Chiocca EA
Nat Med; 2012 Dec; 18(12):1827-34. PubMed ID: 23178246
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase 6 inhibition enhances oncolytic viral replication in glioma.
Nakashima H; Kaufmann JK; Wang PY; Nguyen T; Speranza MC; Kasai K; Okemoto K; Otsuki A; Nakano I; Fernandez S; Goins WF; Grandi P; Glorioso JC; Lawler S; Cripe TP; Chiocca EA
J Clin Invest; 2015 Nov; 125(11):4269-80. PubMed ID: 26524593
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib Treatment Sensitizes Oncolytic HSV-1-Treated Tumors to NK Cell Immunotherapy.
Yoo JY; Jaime-Ramirez AC; Bolyard C; Dai H; Nallanagulagari T; Wojton J; Hurwitz BS; Relation T; Lee TJ; Lotze MT; Yu JG; Zhang J; Croce CM; Yu J; Caligiuri MA; Old M; Kaur B
Clin Cancer Res; 2016 Nov; 22(21):5265-5276. PubMed ID: 27390350
[TBL] [Abstract][Full Text] [Related]
9. NK cell tumor therapy modulated by UV-inactivated oncolytic herpes simplex virus type 2 and checkpoint inhibitors.
Wang Y; Jin J; Li Y; Zhou Q; Yao R; Wu Z; Hu H; Fang Z; Dong S; Cai Q; Hu S; Liu B
Transl Res; 2022 Feb; 240():64-86. PubMed ID: 34757194
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activities of valproic acid on Epstein-Barr virus-associated T and natural killer lymphoma cells.
Iwata S; Saito T; Ito Y; Kamakura M; Gotoh K; Kawada J; Nishiyama Y; Kimura H
Cancer Sci; 2012 Feb; 103(2):375-81. PubMed ID: 22017376
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibitors impair NK cell viability and effector functions through inhibition of activation and receptor expression.
Rossi LE; Avila DE; Spallanzani RG; Ziblat A; Fuertes MB; Lapyckyj L; Croci DO; Rabinovich GA; Domaica CI; Zwirner NW
J Leukoc Biol; 2012 Feb; 91(2):321-31. PubMed ID: 22124136
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of CD70-specific CAR T treatment by IFN-γ released from oHSV-1-infected glioblastoma.
Zhu G; Zhang J; Zhang Q; Jin G; Su X; Liu S; Liu F
Cancer Immunol Immunother; 2022 Oct; 71(10):2433-2448. PubMed ID: 35249119
[TBL] [Abstract][Full Text] [Related]
13. The histone deacetylase inhibitor valproic acid enhances equine herpesvirus type 1 (EHV-1)-mediated oncolysis of human glioma cells.
White MC; Frampton AR
Cancer Gene Ther; 2013 Feb; 20(2):88-93. PubMed ID: 23306611
[TBL] [Abstract][Full Text] [Related]
14. Systemic delivery of glycosylated-PEG-masked oncolytic virus enhances targeting of antitumor immuno-virotherapy and modulates T and NK cell infiltration.
Liang Y; Wang B; Chen Q; Fu X; Jiang C; Lin Z; Zhuang Q; Zeng Y; Liu X; Zhang D
Theranostics; 2023; 13(15):5452-5468. PubMed ID: 37908722
[No Abstract] [Full Text] [Related]
15. Valproic acid cooperates with hydralazine to augment the susceptibility of human osteosarcoma cells to Fas- and NK cell-mediated cell death.
Yamanegi K; Yamane J; Kobayashi K; Kato-Kogoe N; Ohyama H; Nakasho K; Yamada N; Hata M; Fukunaga S; Futani H; Okamura H; Terada N
Int J Oncol; 2012 Jul; 41(1):83-91. PubMed ID: 22576685
[TBL] [Abstract][Full Text] [Related]
16. PKR induces TGF-β and limits oncolytic immune therapy.
Hong B; Sahu U; Mullarkey MP; Hong E; Pei G; Yan Y; Otani Y; Banasavadi-Siddegowda Y; Fan H; Zhao Z; Yu J; Caligiuri MA; Kaur B
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36796878
[TBL] [Abstract][Full Text] [Related]
17. Valproic acid inhibits interferon-γ production by NK cells and increases susceptibility to Listeria monocytogenes infection.
Soria-Castro R; Chávez-Blanco AD; García-Pérez BE; Wong-Baeza I; Flores-Mejía R; Flores-Borja F; Estrada-Parra S; Estrada-García I; Serafín-López J; Chacón-Salinas R
Sci Rep; 2020 Oct; 10(1):17802. PubMed ID: 33082490
[TBL] [Abstract][Full Text] [Related]
18. Hydroxyurea upregulates NKG2D ligand expression in myeloid leukemia cells synergistically with valproic acid and potentially enhances susceptibility of leukemic cells to natural killer cell-mediated cytolysis.
Lu X; Ohata K; Kondo Y; Espinoza JL; Qi Z; Nakao S
Cancer Sci; 2010 Mar; 101(3):609-15. PubMed ID: 20028385
[TBL] [Abstract][Full Text] [Related]
19. Valproic acid upregulates NKG2D ligand expression through an ERK-dependent mechanism and potentially enhances NK cell-mediated lysis of myeloma.
Wu X; Tao Y; Hou J; Meng X; Shi J
Neoplasia; 2012 Dec; 14(12):1178-89. PubMed ID: 23308050
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of TrkB Expression and Signaling by Valproic Acid and Other Histone Deacetylase Inhibitors.
Dedoni S; Marras L; Olianas MC; Ingianni A; Onali P
J Pharmacol Exp Ther; 2019 Sep; 370(3):490-503. PubMed ID: 31308194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]